BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Peginesatide regulatory update

FDA's Oncologic Drugs Advisory Committee voted 15-1 with 1 abstention that Affymax's peginesatide has a favorable benefit-risk profile to treat anemia in patients with chronic kidney disease who are on dialysis. The panel agreed that Affymax demonstrated peginesatide's non-inferiority to standard of care epoetin alfa for efficacy and safety...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >